Gilead says Q2 2026 revenue growth is driven by Biktarvy, Descovy and Yeztugo demand, pricing gains
GILD•Q2 revenue growth driven by HIV and PrEP products
Gilead posted Q2 2026 revenue of $7.8 billion, driven by HIV growth, led by Biktarvy demand and pricing.
- HIV sales rose 12% to $5.69 billion; Biktarvy increased 7% to $3.77 billion, supported by channel mix and inventory build.
- PrEP sales more than doubled to $1.03 billion; Descovy for PrEP rose 60% to $801 million, and Yeztugo reached $232 million.
- Liver disease sales climbed 10% to $877 million on higher demand in PBC, HBV and HDV, partly offset by fewer HCV starts.
- Full-year product sales guidance rose to $30.1 billion-$30.4 billion; HIV growth outlook increased to 9%-10%.
